Drug Profile
REN 1053
Latest Information Update: 17 Oct 2003
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Cardiotonics; Vasodilators
- Mechanism of Action Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 17 Apr 1998 Discontinued - Preclinical for Heart Failure in Germany